Recent advances using CAR T cells in lymphoid malignancies have made it clear that manipulation of the host immune system can radically alter the course of a cancer. Although there have been lifesaving responses in some patients, all too many patients have inadequate responses. Some patients and tumor types have been more amenable to CAR T cell therapies than others, despite similar levels of antigen expression, uniformity, and density. The exact mechanisms by which CAR T cells induce tumor cell death are unknown, and may be due to a combination of multiple T cell effector functions that ultimately result in cell death, potentially by triggering programmed cell death in tumor cells. Our overall hypothesis is that CAR T cells mediate tumor cell death by inducing programmed cell death (PCD) pathways in target cells. A logical corollary of this hypothesis is that one potential mechanism of resistance, which has received scant attention, is genetic or functional resistance to PCD in the target tumor cells. Furthermore, we hypothesize that the state of PCD constituents in tumor cells confers sensitivity or resistance to T-cell mediated killing, and that this relative resistance can be overcome with drugs that enhance PCD signaling in tumor cells. Finally, because systemically administered drugs that enhance PCD signaling may also affect CAR T cells, we propose genetic engineering approaches to render CAR T cells resistant to candidate PCD-enhancing drugs. This is a collaborative project between an expert in CAR T cells and immunology and an expert in programmed cell pathways and tumor biology. Together we aim to define the effector functions of T cells that induce tumor cell death (Aim 1), define the programmed cell death pathways in tumors that confer sensitivity or resistance to CAR T cell mediated killing (Aim 2), and use innovative strategies to enhance CAR T cell killing of tumor cells by manipulating PCD pathways using small molecule drugs in combination with genetic engineering of the CAR T cells.

Public Health Relevance

Immune therapy has become a standard treatment for multiple types of cancers and ultimately relies on T cells to kill tumor cells; however, we don?t yet fully understand the relationship between how T cells kill tumors and how cell death pathways in tumors lead to their death. CAR T cells are engineered T cells that kill lymphoid tumors by targeting a specific protein on their surface, and are now standard treatment for lymphoid cancers. We propose to examine the mechanisms by which CAR T cells kill tumors, and define the programmed cell death pathways in tumor cells that enable susceptibility and resistance to CAR T cell killing, with the goal of using specific combinations of drugs and engineering approaches to enhance T cell-mediated tumor killing.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
1R01CA249062-01A1
Application #
10120167
Study Section
Special Emphasis Panel (ZRG1)
Program Officer
Bourcier, Katarzyna
Project Start
2021-01-07
Project End
2025-12-31
Budget Start
2021-01-07
Budget End
2021-12-31
Support Year
1
Fiscal Year
2021
Total Cost
Indirect Cost
Name
Massachusetts General Hospital
Department
Type
DUNS #
073130411
City
Boston
State
MA
Country
United States
Zip Code